<a href="https://laohu8.com/S/QTTB">Q32 Bio Inc.</a> reports Q3 net loss of $7.4 million
Q32 Bio Inc. reported a net loss of $7.4 million, or $0.60 per share, for the third quarter of 2025, compared to a net loss of $17.6 million, or $1.46 per share, for the same period in 2024. Research and development expenses decreased to $3.6 million from $14.3 million, primarily due to lower development costs for bempikibart, reduced expenses from the discontinued ADX-097 program, and lower personnel-related costs. General and administrative expenses were $4.0 million, down from $4.5 million, mainly due to decreased personnel and professional service costs. As of September 30, 2025, cash and cash equivalents totaled $49.0 million, expected to fund operations into 2027. The company completed enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial, with a topline data readout expected in mid-2026, and continues dosing in the Part A open-label extension.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE22917) on November 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.